Article

Added-value of whole exome and RNA Sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel

2022-02-10

Abstract excerpt

<h4>Importance</h4> While comprehensive tumor molecular profile by whole exome and RNA sequencing (WES/RNA-Seq) is now feasible in routine practice, it remains unclear whether this increases therapeutic options as compared to a more limited targeted gene panel (TGP) plus array-based comparative genomic hybridization (aCGH) in advanced cancer patients. <h4>Objective</h4> To determine the added value of WES/RNA-Seq...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5b7492a3-1bf1-5bfa-b8f5-35bece5f600b
DOI: 10.1101/2022.02.08.22270301

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Added-value of whole exome and RNA Sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panelDOI 10.1101/2022.02.08.22270301Read

Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor boardSemantic proximity Read

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersSemantic proximity Read

How to read a next-generation sequencing report—what oncologists need to knowSemantic proximity Read

Translational and clinical comparison of whole genome and transcriptome to panel sequencing in precision oncologySemantic proximity Read

Comparison of whole-exome, whole-transcriptome genomic profiling and targeted sequencing with 50-gene panels in advanced solid tumorsSemantic proximity Read

Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors.Semantic proximity Read

Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced CancersSemantic proximity Read

Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline - relevance for additional therapeutic options.Semantic proximity Read

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsSemantic proximity Read

Clinical Benefit and Agenda for Clinical Sequencing Using Cancer Panel Testing: A Retrospective Clinical StudySemantic proximity Read

Precision oncology based on omics data: The NCT Heidelberg experienceSemantic proximity Read

Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialSemantic proximity Read